Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care These data demonstrate Roche's commitment to providing options ...

Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients[1],[2] Positive opinion reinforces Phase 3 TRIANGLE study results by the European MCL ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...